CRISPR Therapeutics shows strong gene-editing pipeline with upcoming catalysts and solid cash position.

CRISPR Therapeutics is a mid-sized biotech firm specializing in CRISPR gene-editing therapies, with a diversified pipeline and two approved treatments, including CASGEVY for sickle cell disease. The company's stock has declined 38% from its 52-week high, but upcoming clinical data and trial initiations could drive momentum. CASGEVY's proven efficacy, expanding market access, and CRISPR's strong cash reserves present a favorable risk/reward profile for investors.